Emergence of the E484K Mutation in SARS-CoV-2 Lineage B.1.1.220 in Upstate New York

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was partially funded by the Defense Health Program (DHP) Operations & Maintenance (O&M).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB Approval has been granted for this study by Rochester Regional Health under protocol "IRB 2051 C Lesho: Enhanced Surveillance to Prevent Nosocomial Transmission of SARS-CoV-2 at Rochester Regional Health"

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes